Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 3/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27939661 | 0.89 | SLC13A5 (0.48) | TAAR1SLC13A5HTR2AHTR2CKDM1A | |
| SCHEMBL28199240 | 0.85 | SLC13A5 (0.50) | SLC13A5HTR2AHTR2CKDM1AMAOA | |
| SCHEMBL1265988 | 0.85 | KDM1A (0.46) | SLC13A5HTR2AHTR2CKDM1AMAOA | |
| SCHEMBL29587038 | 0.85 | KDM1A (0.46) | SLC13A5HTR2AHTR2CKDM1AMAOA | |
| Hydrochloric Acid SCHEMBL16797857 | 0.83 | KDM1A (0.44) | SLC13A5HTR2AHTR2CKDM1AMAOA | |
| Hydrochloric Acid SCHEMBL5900832 | 0.83 | KDM1A (0.44) | SLC13A5HTR2AHTR2CKDM1AMAOA | |
| SCHEMBL12093550 | 0.83 | SLC13A5 (0.51) | SLC13A5HTR2AHTR2CKDM1AMAOA | |
| SCHEMBL8220219 | 0.82 | SLC13A5 (0.48) | SLC13A5HTR2AHTR2CKDM1AMAOA | |
| SCHEMBL18892461 | 0.81 | SLC13A5 (0.50) | SLC13A5HTR2AHTR2CKDM1AMAOA | |
| SCHEMBL5780541 | 0.81 | SLC13A5 (0.54) | SLC13A5HTR2AHTR2CKDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137506-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | CURASEN THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2023225021-A1 | COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) | CURASEN THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230167119-A1 | DIAMINOPYRAZOLO[1,5-A]PYRIMIDINE-6-CARBONITRILE COMPOUNDS AS ADENOSINE 2A RECEPTOR AND ADENOSINE 2B RECEPTOR ANTAGONIST | Bugworks Research, Inc. | 2023-06-01 | — | — | US | disclosed |
| US-20230167119-A1 | DIAMINOPYRAZOLO[1,5-A]PYRIMIDINE-6-CARBONITRILE COMPOUNDS AS ADENOSINE 2A RECEPTOR AND ADENOSINE 2B RECEPTOR ANTAGONIST | Bugworks Research, Inc. | 2023-06-01 | — | — | US | disclosed |
| WO-2022149167-A1 | DIAMINOPYRAZOLO[1,5-A]PYRIMIDINE-6-CARBONITRILE COMPOUNDS AS ADENOSINE 2A RECEPTOR AND ADENOSINE 2B RECEPTOR ANTAGONIST | BUGWORKS RESEARCH INDIA PVT LTD (IN) | 2022-07-14 | — | — | WO | disclosed |
| EP-3820860-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | Lieber Institute, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167119-A1 | DIAMINOPYRAZOLO[1,5-A]PYRIMIDINE-6-CARBONITRILE COMPOUNDS AS ADENOSINE 2A RECEPTOR AND ADENOSINE 2B RECEPTOR ANTAGONIST | ADORA2A, ADORA2B, ADORA1 | TAAR1 176/4885SLC13A5 776/4885HTR2A 31/4885 |
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | NNT, NAMPT, NQO1 | TAAR1 4156/4885SLC13A5 319/4885HTR2A 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.